NCT06592287View on ClinicalTrials.gov

The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Advanced Gastric Cancer
Interventions
DRUG

Adebrelimab + Apatinib + Lrinotecan liposome

"Adebrelimab 1200 mg, iv. q3w~Apatinib 250 mg po qd~Lrinotecan liposome 80mg/m2, iv. q3w~Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years."

Trial Locations (1)

430030

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan

All Listed Sponsors
lead

Xianglin Yuan

OTHER

NCT06592287 - The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter